Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060238 | 0.95 | HTT (0.60) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL764273 | 0.84 | CTSL (0.64) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL6044833 | 0.82 | HTT (0.76) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL6898353 | 0.81 | HTT (0.78) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL319161 | 0.81 | HTT (1.00) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL18254066 | 0.80 | HTT (0.81) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL21559798 | 0.80 | HTT (0.72) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL15745834 | 0.80 | FOLH1 (0.57) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL17350365 | 0.80 | HTT (0.67) | HTTLMNASMN1; SMN2FOLH1TGM2 | |
| SCHEMBL12088080 | 0.80 | HTT (0.67) | HTTLMNASMN1; SMN2FOLH1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087700-B | Spirocyclic tetrahydroquinazolines | 苏州亚盛药业有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-113087700-A | Spirocyclic tetrahydroquinazolines | 苏州亚盛药业有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-8445514-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-21 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8008299-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080318973-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008153902-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | HTT 704/4885LMNA 2503/4885SMN1; SMN2 2074/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | HTT 948/4885LMNA 2991/4885SMN1; SMN2 4385/4885 |
| US-20080318973-A1 | Urotensin II receptor antagonists | UTS2R, BDKRB2, AGTR2 | HTT 2122/4885LMNA 2142/4885SMN1; SMN2 2919/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | HTT 704/4885LMNA 2503/4885SMN1; SMN2 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.